This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Glesatinib
DrugBank Accession Number
DB06302
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 619.71
Monoisotopic: 619.152338423
Chemical Formula
C31H27F2N5O3S2
Synonyms
  • Glesatinib
External IDs
  • MG-90265
  • MG-90265X
  • MG90265
  • MG90265X
  • MGCD-265
  • MGCD265

Pharmacology

Indication

Investigated for use/treatment in cancer/tumors (unspecified).

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbaloparatideThe therapeutic efficacy of Abaloparatide can be decreased when used in combination with Glesatinib.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Glesatinib.
CarbimazoleThe therapeutic efficacy of Carbimazole can be decreased when used in combination with Glesatinib.
FollitropinThe therapeutic efficacy of Follitropin can be decreased when used in combination with Glesatinib.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Glesatinib.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Glesatinib.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Glesatinib.
MethimazoleThe therapeutic efficacy of Methimazole can be decreased when used in combination with Glesatinib.
Parathyroid hormoneThe therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Glesatinib.
Potassium IodideThe therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Glesatinib.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
7Q29OXD98N
CAS number
936694-12-1
InChI Key
YRCHYHRCBXNYNU-UHFFFAOYSA-N
InChI
InChI=1S/C31H27F2N5O3S2/c1-40-13-12-34-17-20-4-8-24(36-18-20)28-16-25-30(43-28)27(10-11-35-25)41-26-9-7-22(15-23(26)33)37-31(42)38-29(39)14-19-2-5-21(32)6-3-19/h2-11,15-16,18,34H,12-14,17H2,1H3,(H2,37,38,39,42)
IUPAC Name
3-(3-fluoro-4-{[2-(5-{[(2-methoxyethyl)amino]methyl}pyridin-2-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)-1-[2-(4-fluorophenyl)acetyl]thiourea
SMILES
COCCNCC1=CC=C(N=C1)C1=CC2=NC=CC(OC3=CC=C(NC(=S)NC(=O)CC4=CC=C(F)C=C4)C=C3F)=C2S1

References

General References
Not Available
ChemSpider
52084900
ChEMBL
CHEMBL3989914
ZINC
ZINC000113139653
Wikipedia
Glesatinib

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)2
1CompletedTreatmentAdvanced Malignancies2
1CompletedTreatmentCancer, Advanced1
1TerminatedTreatmentAdvanced Malignancies, Non-small Cell Lung Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility8.1e-05 mg/mLALOGPS
logP5.42ALOGPS
logP5.46ChemAxon
logS-6.9ALOGPS
pKa (Strongest Acidic)9.27ChemAxon
pKa (Strongest Basic)8.28ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area97.4 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity166.04 m3·mol-1ChemAxon
Polarizability63.77 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at March 19, 2008 16:23 / Updated at February 21, 2021 18:52